MDMA enhances early visual processing for salient socio-emotional stimuli.
Connor J Haggarty, Anya K. Bershad, Mahesh K Kumar, Royce Lee, Harriet de Wit
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial |
|---|---|
| Interventions | MDMA Methamphetamine Placebo |
| Measures | N170 |
| Topics | MDMA |
| Key findings | MDMA enhanced the N170 event-related component for happy and angry faces relative to neutral faces, whereas methamphetamine did not affect this measure. Neither drug altered other components of the response to emotional faces. The authors propose that MDMA may specifically enhance early visual processing of socio-emotional stimuli, with possible therapeutic implications for social anxiety and other psychiatric disorders. |
Abstract
3,4-methylenedioxymethamphetamine (MDMA) has long been used non-medically, and it is currently under investigation for its potential therapeutic benefits. Both uses may be related to its ability to enhance empathy, sociability, emotional processing and its anxiolytic effects. However, the neural mechanisms underlying these effects, and their specificity to MDMA compared to other stimulants, are not yet fully understood. Here, using electroencephalography (EEG), we investigated the effects of MDMA and a prototypic stimulant, methamphetamine (MA), on early visual processing of socio-emotional stimuli in an oddball emotional faces paradigm. Specifically, we examined whether MDMA or MA enhance the processing of facial expressions, compared to placebo, during the early stages of visual perception. MDMA enhanced an event-related component that is sensitive to detecting faces (N170), specifically for happy and angry expressions compared to neutral faces. MA did not affect this measure, and neither drug altered other components of the response to emotional faces. These findings provide novel insights into the neural mechanisms underlying the effects of MDMA on socio-emotional processing and may have implications for the therapeutic use of MDMA in the treatment of social anxiety and other psychiatric disorders.